Replies to post #250757 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

I’ll Be Glad When Anavex Is a Soporific

The major prescription insomnia drugs market, led by Belsomra, Ambien, and Lunesta, has been declining in value due to the expiration of patents and the entry of cheaper generics. These drugs’ U.S. sales total about $1.4 billion. However, the non-prescription or OTC sleeping pills market, valued at $576 million, is growing faster.

https://blog.marketresearch.com/top-6-things-to-know-about-the-28-billion-sleep-market

Ok, if Anavex captures half of that market (of $1,400,000,000) each year, do some fuzzy calculating of what an AVXL share could be purchased for. Be safe. Presume that at that time there will be 60 million outstanding shares.

Me, I’m bolder. I think Anavex could capture about 90% of the sleeping pill market.

[jimmy667]

Yes sleep as a follow on indication after blarcamisine has been in general use for a few years would be fantastic and dwarf the CNS indications geometrically. 2023 Global sleep aids market projected to exceed $79.85 Billion by 2023. 2019 was $67.37 Billion and growing at 6.32% a year. This would make blarcamisine one of the biggest blockbuster drugs in history if Anavex can eventually get approval as a safe and effective sleep aid.